Sunil Reddy

Publications

• A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Duvic M, Reddy SA, Pinter-Brown L, Korman NJ, Zic J, Kennedy DA, Lorenz J, Sievers EL, Kim YH. Clin Cancer Res. 2009; 15 (19): 6217-24
• Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome. Woo DK, Jones CR, Vanoli-Storz MN, Kohler S, Reddy S, Advani R, Hoppe RT, Kim YH. Arch Dermatol. 2009; 145 (6): 667-74
• Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab. Morales AV, Advani R, Horwitz SM, Riaz N, Reddy S, Hoppe RT, Kim YH. J Am Acad Dermatol. 2008; 59 (6): 953-7
• Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study. McCormick AA, Reddy S, Reinl SJ, Cameron TI, Czerwinkski DK, Vojdani F, Hanley KM, Garger SJ, White EL, Novak J, Barrett J, Holtz RB, Tusé D, Levy R. Proc Natl Acad Sci U S A. 2008; 105 (29): 10131-6
• Molecular rescue of tumour-specific T cell receptor idiotype from T cell lymphomas. Reddy SA, Levy R. Br J Haematol. 2004; 124 (5): 626-8
• CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. Liu HL, Hoppe RT, Kohler S, Harvell JD, Reddy S, Kim YH. J Am Acad Dermatol. 2003; 49 (6): 1049-58
• T cell antigen receptor vaccines for active therapy of T cell malignancies. Reddy SA, Okada C, Wong C, Bahler D, Levy R. Ann N Y Acad Sci. 2001: 941 97-105
• Favorable treatment outcome in non-Hodgkin's lymphoma patients with "poor" mobilization of peripheral blood progenitor cells. Stockerl-Goldstein KE, Reddy SA, Horning SF, Blume KG, Chao NF, Hu WW, Johnston LF, Long GD, Strober S, Wong RM, Feiner RH, Kobler S, Negrin RS. Biol Blood Marrow Transplant. 2000; 6 (5): 506-12